By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Corvus Pharmaceuticals 

863 Mitten Road, Suite 102

Burlingame  California    U.S.A.
Phone: 650-900-4520 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Corvus Pharma


Start Up

Company News
Corvus Pharma Announces Interim Results From Ongoing Phase I/Ib Study Demonstrating Safety And Clinical Activity Of Lead Checkpoint Inhibitor CPI-444 In Patients With Advanced Cancers 4/4/2017 11:37:56 AM
Corvus Pharma To Reschedule R&D Day Due To Severe Winter Storm In The New York Tri-State Area 3/13/2017 8:16:47 AM
Corvus Pharma Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Business Update 3/10/2017 8:52:25 AM
Vernalis PLC (VNLPY.PK) Achieves A $3 Million Milestone Payment From Corvus Pharma 2/14/2017 9:26:17 AM
Corvus Pharma Announces Expansion Of Renal Cell Carcinoma Cohort In Ongoing Phase I/Ib Clinical Study Of Lead Checkpoint Inhibitor CPI-444 1/10/2017 6:56:57 AM
Corvus Pharma Announces Preliminary Phase 1/1b Clinical Data With Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety And Evidence Of Anti-Tumor Activity As A Single Agent In Patients With Advanced Refractory Cancers 11/11/2016 9:04:42 AM
Corvus Pharma Announces Third Quarter Financial Results and Provides Business Update 11/4/2016 9:54:24 AM
Corvus Pharma Announces Biomarker Findings From Phase I/IIb Study Of Lead Oral Checkpoint Inhibitor CPI-444 Presented At ESMO 2016 Congress 10/10/2016 8:49:40 AM
Corvus Pharma To Present Data On Lead Oral Checkpoint Inhibitor CPI-444 At ESMO 2016 Congress 10/4/2016 7:56:17 AM
Corvus Pharma Announces Preclinical And Preliminary Clinical Biomarker Data Of Lead Oral Checkpoint Inhibitor CPI-444 Presented At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 9/26/2016 7:56:17 AM